Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.51 |
| ▸ | GCGR | P47871 | 6/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.37 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL485432 | 0.91 | CXCR2 (0.54) | CXCR2CXCR5ERAP1GPR132DRD2 | |
| SCHEMBL485510 | 0.89 | CXCR2 (0.56) | CXCR2CXCR5ERAP1GPR132CNR2 | |
| SCHEMBL485420 | 0.86 | CXCR2 (0.51) | CXCR2GCGRCXCR5ERAP1GPR132 | |
| SCHEMBL485105 | 0.86 | CXCR2 (0.45) | CXCR2CXCR5ERAP1GPR132DRD2 | |
| SCHEMBL484896 | 0.86 | CXCR2 (0.56) | CXCR2CXCR5ERAP1 | |
| SCHEMBL484989 | 0.86 | CXCR2 (0.61) | CXCR2GCGRMAOAMAOBCXCR5 | |
| SCHEMBL485249 | 0.85 | CXCR2 (0.55) | CXCR2GCGRCXCR5ERAP1GPR132 | |
| SCHEMBL27693222 | 0.85 | GCGR (0.40) | CXCR2GCGRHRH3MAOAMAOB | |
| SCHEMBL485331 | 0.85 | CXCR2 (0.49) | CXCR2CXCR5ERAP1GPR132DRD2 | |
| SCHEMBL485218 | 0.84 | CXCR2 (0.56) | CXCR2CXCR5ERAP1GPR132FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | claimed |
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| EP-1836158-B1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1836158-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | Sanofi-Aventis Deutschland GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069656-A1 | FUSED BICYCLIC CARBOXAMIDE DERIVATIVES FOR USE AS CXCR2 INHIBITORS IN THE TREATMENT OF INFLAMMATION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885GCGR 209/4885HRH3 834/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885GCGR 209/4885HRH3 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.